Suloctidil

Summary

Suloctidil (CHEMBL404849) is an approved small molecule (ATC C04AX19); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C04AX19
• Indications: 1 condition
• Chemistry: 337.6 Da · C20H35NOS

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL404849
Name	Suloctidil
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5354
ChEBI	CHEBI:91639
ATC	C04AX19
Molecular formula	C20H35NOS
Molecular weight	337.6
InChIKey	BFCDFTHTSVTWOG-UHFFFAOYSA-N

SMILES: CCCCCCCCNC(C)C(C1=CC=C(C=C1)SC(C)C)O

IUPAC name: 2-(octylamino)-1-(4-propan-2-ylsulfanylphenyl)propan-1-ol

ChEBI definition: An aryl sulfide that is benzene substituted by 1-hydroxy-2-(octylamino)propyl and propan-2-ylsulfanediyl groups at positions 1 and 4, respectively.

Also known as: Bemperil, Cerebro, Circleton, CP-556S, Dulasi, Duloctil, Euvasal, Fluversin, Fluvisco, Hemoantin, Iangene, Loctidon

Patent coverage: 2,674 distinct patent families (5,496 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 48 (assay-derived). Sample: Nuclear receptor ROR-gamma, Survival motor neuron protein, Prelamin-A/C, 4’-phosphopantetheinyl transferase ffp, Muscarinic acetylcholine receptor M4, 5-hydroxytryptamine receptor 2B, Tyrosine-protein kinase Fyn, Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, Histamine H2 receptor.

Bioactivity

ChEMBL activities: 65 potent at pChembl ≥ 5 of 88 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q01827	8.89	AC50	1.3	nM	CHEMBL_ACT_25197366
CYP2C9	8.3	Potency	5	nM	CHEMBL_ACT_5077150
CYP2C9	8.3	AC50	5.01	nM	CHEMBL_ACT_6067002
SIGMAR1	7.31	Ki	49.3	nM	CHEMBL_ACT_7814421
HRH2	7.05	Ki	88.5	nM	CHEMBL_ACT_7812299
HRH2	6.97	IC50	108.1	nM	CHEMBL_ACT_7812298
SIGMAR1	6.93	IC50	117.2	nM	CHEMBL_ACT_7814420
HTR1A	6.67	AC50	216.2	nM	CHEMBL_ACT_25165048
P19327	6.51	Ki	310.6	nM	CHEMBL_ACT_7814403
KCNH2	6.37	AC50	430	nM	CHEMBL_ACT_25117650
ADRA2C	6.3	Ki	500.7	nM	CHEMBL_ACT_7810201
P19327	6.26	IC50	543.5	nM	CHEMBL_ACT_7814402
HTR2B	6.22	Ki	597.5	nM	CHEMBL_ACT_7814409
CHRM4	6.2	Ki	636.1	nM	CHEMBL_ACT_7812331
SLC6A4	6.18	Ki	665.8	nM	CHEMBL_ACT_7814419
DRD3	6.17	AC50	671	nM	CHEMBL_ACT_25194547
DRD3	6.15	Ki	714.5	nM	CHEMBL_ACT_7812267
FYN	6.14	IC50	722.1	nM	CHEMBL_ACT_7814392
ADRA2A	6.12	Ki	758.7	nM	CHEMBL_ACT_7810197
EGFR	6.1	IC50	794.4	nM	CHEMBL_ACT_7814390
HTR2B	6.03	IC50	939	nM	CHEMBL_ACT_7814408
CHRM3	6.01	Ki	980	nM	CHEMBL_ACT_7812329
CYP2D6	6	Potency	1000	nM	CHEMBL_ACT_4986022
CYP2D6	6	AC50	1000	nM	CHEMBL_ACT_5987077
CHRM1	5.96	Ki	1085	nM	CHEMBL_ACT_7812325
SLC6A4	5.92	AC50	1192	nM	CHEMBL_ACT_25151351
SLC6A4	5.9	IC50	1253	nM	CHEMBL_ACT_7814418
SLC6A2	5.86	AC50	1389	nM	CHEMBL_ACT_25146024
SLC6A2	5.86	Ki	1389	nM	CHEMBL_ACT_7810209
SLC6A2	5.85	IC50	1400	nM	CHEMBL_ACT_7810208

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).